Zhong Suansui aspires to be the richest man in Asia!

Zhong Suansui

In 2018, Nongfu Spring’s market share was 28.
3%, and it has been the market leader for several consecutive years
.

In September of this year, Nongfu Spring was listed on the Hong Kong Stock Exchange, with a market value of HK$445.
3 billion.
Together with Wantai Biopharmaceuticals, Zhong Suisui surpassed Ma Yun and Ma Huateng to become China’s new richest man in one fell swoop
.
However, as the stock price opened higher and lowered lower, the gains narrowed and the market value fell back to 385 billion Hong Kong dollars.
Zhong Suijuan ranked third among the richest in China
.

Domestic HPV vaccine tycoon, the world's first hepatitis E vaccine

Another identity of Zhong Suansui is the chairman of Wantai Biopharmaceuticals
.

Established in 1991, Wantai Biotech is a high-tech enterprise engaged in the development and production of biological diagnostic reagents and vaccines
.
In 2001, Zhong Suansui spent 17.
1 million yuan to buy 95% of the shares of Wantai Biotech through Yangshengtang and became the actual controlling shareholder
.
Fortunately, in 2020, both test strips and HPV vaccines will be hotspots in the market.
Wantai Biotech is not only a domestic leader in in vitro diagnostic reagents, but also the first domestically approved HPV vaccine company
.

Zhong Suisui pays close attention to the innovative research and development of Wantai Bio.
This year, the new coronavirus (2019-nCoV) antibody detection kit (magnetic particle chemiluminescence method) developed by the company has been approved by the State Drug Administration and is currently approved.
One of the two passed new coronavirus antibody detection reagents (magnetic particle chemiluminescence method)
.
The specificity of the new coronavirus total antibody detection reagent reaches 100%, and the total antibody sensitivity is as high as 94.
8% or more
.

Wantai Biotechnology has been in the vaccine industry for more than 15 years, and currently two products have been approved for the market, namely the recombinant hepatitis E vaccine and the bivalent cervical cancer vaccine
.

The first vaccine product is "Yikening Hecolin" recombinant hepatitis E vaccine, which is the world's first hepatitis E vaccine
.
The bivalent HPV vaccine "Xinkening Cecolin" developed by the company was approved for listing on December 30, 2019.
It is the first HPV vaccine to be marketed in China and is expected to lead domestic counterparts by about two years
.

In April of this year, as soon as Wantai Biotech went public, its market value soared by more than 30 times, from about 2.
8 billion to 85 billion, directly bringing more than 80 billion fortune to Zhong Sui Sui
.

On the 2020 Hurun Rich List and the 2020 Forbes China Rich List, Zhong Suisui ranks third! In 2019, Zhong Suisui's net worth was only more than 10 billion yuan.
In 2020, through the listing of Nongfu Spring and Wantai Biological, it will rise to 359.
6 billion yuan, a surge of 345.
8 billion in a year!

Conclusion : I started a business at the age of 39.
In 27 years, Zhong Sui Sui, who was a mason, has built a huge capital building.
The hero does not ask where he comes from, and entrepreneurship changes life
.